Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Caliper LS Receives $1.1 Million Task Order from the EPA's ToxCast™ Screening Program

Published: Wednesday, August 20, 2008
Last Updated: Wednesday, August 20, 2008
Bookmark and Share
This task order was issued pursuant to a contract that Caliper was awarded by the EPA in April 2007 under the ToxCast program.

Caliper Life Sciences, Inc. has announced that it has received a $1.1 million task order under the United States Environmental Protection Agency's (EPA) ToxCast™ screening program. This task order was issued pursuant to a contract that Caliper was awarded by the EPA in April 2007 under the ToxCast program.

The contract provides for up to $69 million of screening services throughout five years, although the specific dollar value is subject to the actual volume of testing requested by the EPA as well as continued government funding for the ToxCast program.

To date, Caliper has received task orders under this EPA contract totaling approximately $3.6 million, including the new $1.1million task order. This new task order was anticipated and the work associated with this order is expected to be substantially completed during the third quarter of 2008.

Caliper works with the EPA under the ToxCast initiative to develop new approaches to identify chemical compounds that are potentially toxic to the environment. Caliper uses in vitro biochemical assays, which have been validated in the pharmaceutical drug discovery industry, to help predict how chemicals like pesticides will interact with the environment, humans and animals. During the initial phase, Caliper tested 320 well-known chemicals through more than 230 in vitro assays. The new task order will support further screening of this initial set of 320 compounds.

Once the first phase of the ToxCast program is complete, the EPA is expected to begin screening a broader class of compounds to expand the database of bioactivity signatures developed in the first phase. Based on these efforts, the ToxCast screening program will provide the EPA with an efficient tool for screening compounds and prioritizing further toxicity testing.

The ultimate goal is to identify a set of predictive in vitro assays that can supplement or replace in vivo tests currently used for regulatory approval of new environmental chemicals.

Earlier in 2008, the EPA and National Institutes of Health (NIH) announced a collaboration intended to broaden the scope of the ToxCast screening program beyond the EPA, further emphasizing the growing national significance of this initiative.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Caliper Life Sciences Forms Alliance with Horizon Discovery
CDAS expands offering to include screening for targeted cancer drugs using genetically-defined in-vitro human disease models.
Thursday, April 10, 2008
Caliper Life Sciences Awarded EPA Contract
Caliper Discovery Alliances and Services unit will test environmental chemicals under EPA’s ToxCast research program.
Tuesday, April 10, 2007
Caliper Life Sciences Launches Drug Discovery and Development Services Business
Caliper combines in vitro and in vivo services of Novascreen Biosciences and Xenogen Biosciences to form Discovery Alliances & Services.
Tuesday, January 09, 2007
Caliper Strengthens Distribution Channels in China, Hong Kong and India
Leading international distributors expand customer access to Caliper microfluidics and drug discovery technologies.
Monday, February 13, 2006
Caliper Completes Acquisition of NovaScreen
The acquisition combines NovaScreen's screening, profiling and assay development services with Caliper's LabChip® and liquid handling products.
Thursday, October 06, 2005
Caliper Technologies expands Caliper 250 system

Monday, March 10, 2003
Caliper cut's Amphora Discovery's purchase obligations

Tuesday, December 17, 2002
Zymark Supplies HTS Systems to Vertex Pharmaceuticals

Tuesday, October 15, 2002
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Long-Sought Protein Sensor for the ‘Sixth Sense’ Discovered
In a study led by scientists from The Scripps Research Institute (TSRI)the sensor protein for propioception has been identified.
New Anti-Malarial Drug Screening Model
University of South Florida researchers demonstrate novel chemogenomic profiling to identify drug targets for the most lethal strain of malaria.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Giant Molecules Inhibit Ebola Infection
European researchers have designed a "giant" molecule formed by thirteen fullerenes covered by carbohydrates which, by blocking this receptor, are able to inhibit the cell infection by an artificial ebola virus model.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos